Alnylam announces new data from attr amyloidosis programs at the peripheral nerve society's 2021 annual meeting

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced positive results from a phase 3b open-label study conducted to evaluate the safety, efficacy and pharmacokinetics (pk) of patisiran in hereditary attr (hattr) amyloidosis patients with polyneuropathy progression after receiving an orthotopic liver transplant (olt). in patients treated with patisiran, the median reduction in serum ttr levels compared to baseline
ALNY Ratings Summary
ALNY Quant Ranking